{"name":"Michelle Abou-Jaoude","slug":"michelle-abou-jaoude","ticker":"","exchange":"","domain":"","description":"Michelle Abou-Jaoude is a biotech company focused on developing innovative therapies for serious diseases. The company has a pipeline of two drugs, one in Phase 1 and another that is marketed.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"K8","genericName":"K8","slug":"k8","indication":"Non-small cell lung cancer, PD-L1 positive","status":"marketed"}]}],"pipeline":[{"name":"K8","genericName":"K8","slug":"k8","phase":"marketed","mechanism":"K8 is a monoclonal antibody that targets the PD-1 receptor.","indications":["Non-small cell lung cancer, PD-L1 positive","Head and neck squamous cell carcinoma"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}